Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus Infection who are HBeAg-positive Revised Protocol 04, incorporating Protocol Amendments 02, 03, 04 and 05

Trial Profile

Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus Infection who are HBeAg-positive Revised Protocol 04, incorporating Protocol Amendments 02, 03, 04 and 05

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2015

At a glance

  • Drugs Peginterferon lambda-1a (Primary) ; Entecavir; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms LIRA-B
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 28 Dec 2015 Results published in the Journal of Hepatology
    • 30 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Apr 2014 Results at 24 weeks post-treatment presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top